Julien Rossignol
Associate Professor
College of Medicine
Specialty: Neuroscience
CMED 2428
989-774-3405
Lab: 989-774-3192


Julien Rossignol's lab is part of the Field Neurosciences Institute laboratory for Restorative Neurology that he co-directs with Dr. Gary L. Dunbar.

​The Field Neurosciences Institute (FNI) Laboratory for Restorative Neurology​ is part of the Brain Research and Integrative Neuroscience (BRAIN) Center, located on the second floor of the research wing in the Health Professions Building. The research mission of the FNI laboratory is to better understand the mechanisms involved in recovery of function following damage to the central nervous system and to devise strategies to promote these mechanisms in clinically relevant ways. Current research focuses on devising potential treatments for neurodegenerative diseases, particularly Huntington’s disease (HD), Parkinson’s disease (PD), and Alzheimer’s disease (AD).

Follow Us



Julien Rossignol's lab is part of the Field Neurosciences Institute laboratory for Restorative Neurology that he co-directs with Dr. Gary L. Dunbar.

The Field Neurosciences Institute (FNI) Laboratory for Restorative Neurology is part of the Brain Research and Integrative Neuroscience (BRAIN) Center, located on the second floor of the research wing in the Health Professions Building. The research mission of the FNI laboratory is to better understand the mechanisms involved in recovery of function following damage to the central nervous system and to devise strategies to promote these mechanisms in clinically relevant ways. Current research focuses on dendrimer nanomolecule based delivery of genes and drug delivery devising potential treatments for neurodegenerative diseases, particularly Huntington’s disease (HD), Parkinson’s disease (PD), and Alzheimer’s disease (AD), stroke and brain tumor such as glioblastoma multiforme (GBM).

We use an in house PAMAM dendrimer nanomolecules with mixed-surface synthesized by our collaborators, Dr. Ajit Sharma and Dr. Douglas Swanson from the Department of Chemistry and Biochemistry. These dendrimers are non-toxic to cells in vitro and in vivo and has the ability to carry large amounts of cargo (drugs and genes/biomolecules). The surface modification that we have done to the conventional amine surface dendrimers enables these our dendrimers to be less toxic and yet be uptaken by the cells. We have also shown that these modified dendrimer nanomolecules can cross the blood-brain barrier following their systemic injections into the artery and veins in mice.G4 image
Dr. Rossignol (seated right), with collaborators Dr. Dunbar (rear right), Dr. Sharma (rear left) and grad student (seated left) work together on an interdisciplinary project researching Huntington’s disease.
Dr. Rossignol (seated right), with collaborators Dr. Dunbar (rear right), Dr. Sharma (rear left) and grad student (seated left) work together on an interdisciplinary project researching Huntington’s disease.
Current research strategy utilizes viral vectors for the transfection of genes. However, these vectors do not have the ability to carry large plasmids that are in the range of 10-100kb. We use our dendrimer nanomolecules to carry large therapeutic plasmids and deliver to the cells and brain in vitro and in vivo, respectively. This strategy overcomes the issues associated with viral vectors including the safety aspect since these dendrimers are proved to be safe and non-toxic.
Image of gene expression following delivery of 11kb plasmid using dendrimer nanoparticles.
AHA AIREA grant: A novel dendrimer-based delivery platform for endogenous brain repair after stroke – American Heart Association Funded Grant (2018-2020)

Stroke is the leading cause of disability and the fourth leading cause of death amongst adults in the United States; yet, effective restorative therapies are lacking. Stem cell transplantation offers an exciting therapeutic approach; however, there is a large variability in efficacy due to survival problems of transplanted cells in the post-stroke environment. An alternative approach would be to convert endogenous cells already proliferating in response to stroke into functional neurons. Reactive astrocytes are cells widely associated with neural injury including stroke. Engineering astrocytes into functional neurons would decrease scarring of the stroke area while at the same time initiating endogenous brain repair. It is possible to trans-differentiate astrocytes into functional neurons by supplying transcription factors, such as SOX2. To achieve this goal we use a novel class of nanomolecules, PAMAM dendrimers, developed by our collaborators here at CMU, to allow non-viral transfection of DNA into neuron and glia at high efficiency in vivo.
Image of delivery of glial specific SOX2 gene to the stroke brain
Huntington’s disease (HD) is a fatal late-onset neurodegenerative disorder caused by the degeneration of medium spiny neurons (MSNs) in the striatum. The cause of the disease is a CAG repeat expansion in the Huntingtin gene (HTT) leading to production of mutant huntingtin protein. Currently, the only drugs available are palliative. It is well known that trophic factors such brain derived trophic factor (BDNF) is lower in HD brain. Our previous studies have shown that BDNF based therapy is promising in HD by alleviating the signs and symptoms of the disease. However, BDNF cannot cross the blood brain barrier per se. Therefore, our strategy involves use of dendrimer nanomolecules to deliver BDNF plasmid in R6/2 and YAC128 HD mice.
Image of delivery of BDNF gene to the HD brain
Glioblastoma multiforme (GBM) is one of the most common, but an aggressive form of malignant brain tumor in adults arising from glial cells. The disease can be managed by chemotherapy and/or radiotherapy or the tumor can be surgically removed. However, there is no permanent cure. GBM causes inflammation in the brain due to the up-regulation of pro-inflammatory genes leading to invasion and migration of cancer. Previously studies have proven the therapeutic/anti-inflammatory effects of Curcumin (Cur) in Glioblastoma. Since Cur is highly insoluble in organic solvents, we have encapsulated and entrapped Cur in dendrimers making them more water soluble to achieve its delivery in significant amounts to the GBM brain (in mice). Our current work also involves using few more water soluble formulations of Cur and nanomolecules synthesized by our collaborators for GBM.
Image of mouse with glioblastoma
Huntington’s disease (HD) is one of the most debilitating neurological disorders. HD is an autosomal dominant disorder characterized by uncontrolled ballistic movements and by extensive neuronal degeneration, especially of the medium spiny neurons (MSNs) in the striatum. Although it is known that the pathology of HD is the result of a trinucleotide CAG repeat mutation (The Huntington’s Disease Collaborative Research Group, 1993), the mechanisms responsible for the onset of neuronal degeneration and the characteristic motor and cognitive dysfunction have not been elucidated. The only FDA-approved treatment for HD is Tetrabenazine, a drug which depletes monoamine concentrations, but provides only palliative motor benefits and produces adverse side effects which limit its usefulness (Huntington Study Group, 2006). Thus, no current therapies exist that can reduce the constellation of cognitive, motor and psychiatric symptoms, or slow the unrelenting progression of this fatal disorder.

One of the most promising strategies for treating HD has emerged with the advent of cellular therapies. Transplantations of embryonic cells in HD have shown some success, but rejection of these cells and their limited engraftment into the host tissue have mitigated the efficacy of this approach. Although other cell replacement approaches are being developed, transplantation of mesenchymal adult stem cells (MSCs) has gained considerable attention because of their ability to produce and release anti-inflammatory cytokines and neurotrophic factors. Our strategy of transplanting genetically altered MSCs that overexpress a critical neurotrophin, brain derived neurotrophic factor (BDNF), has been targeted for clinical trials, funded by a $17 million grant from the California Institute of Regenerative Medicine to University of California, Davis. Although we believe this strategy is currently one of the most promising therapeutic approaches for slowing the relentless progression of HD, we believe that the efficacy of MSCs for treating HD can be further enhanced by co-transplanting them with induced-pluripotent stem cells (iPSCS), when either or both of these cell population are genetically altered to overexpress BDNF.
BDNF graphic
Huntington’s disease (HD) is a devastating, fatal, autosomal dominant, neurodegenerative disorder, characterized by a relentless loss of cognitive and motor function which affects about 1 in 50,000 people, and which has, to date, remained refractory to any cure or treatment strategy. The use of stem cells and gene-editing techniques offer significant promise, but systemically delivering therapeutic biomolecules throughout the body, especially across the blood-brain barrier, remains a significant obstacle in developing an effective treatment. We are working on developing a novel way of delivering drugs or compound into the brain by studying the safety and biodistribution of a novel family of dendrimers to mesenchymal stem cells (MSCs) as a potential means of delivering therapeutic biomolecules.
Live nanoparticle detection in vivo after injection into the mouse brain.
Live nanoparticle detection in vivo after injection into the mouse brain.
After the recent discovery that infection with Zika during pregnancy can lead to microcephaly in infants, there has been a huge response from the scientific community to determine the virus’ effect on the developing brain. We have been infecting human and mouse neural stem cells with the virus to understand how these cells respond to the virus. Our previous work with mouse neural stem cells has shown that the cells attempt to combat the virus by increasing the expression of genes important for the production of astrocytes, cells in the brain that are important for combating infection, supporting neurons, and regenerating the nervous system after an injury. Future studies include exploring how the virus effects differentiating neural stem cells, determining the inflammatory response to infection, and whether the virus effects the neuronal firing properties of mature neurons.
Julien Rossignol and Olivia Lossia
We are currently looking for student volunteers who would like to gain valuable laboratory experience and those who would like to complete an honors capstone project and are interested in our ongoing neuroscience research. Please contact Dr. Julien Rossignol for more information at rossi1j@cmich.edu​.

  • Dr. Melissa Andrews
    Dr. Melissa Andrews (Research Associate):
    Melissa graduated from Central Michigan University with a master’s degree in Experimental Psychology and a PhD in Neuroscience. Her current research involves optimizing the middle cerebral artery occlusion surgery for ischemic stroke in rats and delivering hSOX2 plasmid using dendrimer nanomolecules alleviate functional deficits following stroke.
  • Bhairavi Srinageshwar
    Dr. Bhairavi Srinageshwar (Research Associate):
    Bhairavi grew up in Chennai, India. She received her Bachelor’s degree in Genetic Engineering from SRM University, Chennai and has a one-year research/work experience in Clinical Genetics lab, Christian Medical College, Vellore. Bhairavi is currently working on dendrimer based gene and drug delivery for Huntington’s disease, Glioblastoma multiforme and stroke.
  • Melissa Resk
    Melissa Resk (Graduate Student):
    Melissa Resk grew up in Richmond, MI. She received her Bachelor's Degree from Central Michigan University with a double major in Neuroscience and Biomedical Sciences. She is currently pursuing her Master's in Neuroscience and working on using dendrimer nanomolecules to deliver therapeutic gene for Stroke and drug for Glioblastoma. She is also looking at the disease-modifying effects of ganglioside GM1 in Huntington's disease.
  • Justin Stadler
    Justin Stadler (Graduate Student):
    Justin grew up in Livonia, Michigan. He received a Bachelor’s degree in Exercise Physiology from Adrian College and his Master’s degree from Central Michigan University. He is currently an instructor of anatomy at the College of Medicine and his current research involves middle cerebral artery occlusion surgery for ischemic stroke in rats and delivering dendrimer nanomolecules to alleviate functional deficits following stroke.
  • John Gallien
    John Gallien (Graduate Student):
    John grew up in Los Gatos, California. He received his Bachelor’s degree in Psychology from San Diego State University. After working as a substance abuse counselor, he went to receive his Master of Science in Clinical Neuropsychology from the University of Texas at Tyler, where his internship focused on the assessment and diagnosis of dementia patients. He went to receive a Master's in Neuroscience at CMU and recently completed a graduate clinical fellowship with MI-LEND. He is currently working on the treatment of stroke and HD using dendrimer nanomolecule delivery.
  • Cassandra Elyse Thompson
    Cassandra Elyse Thompson (Undergraduate Student):
    Cassandra grew up in Portage, Michigan and is currently in her sophomore year of undergraduate degree. She is a neuroscience major working alongside graduate students delivering curcumin using dendrimer nanomolecules as a therapy for Glioblastoma multiforme. She is also involved in the research investigating the migration and bio-distribution of dendrimers in the healthy brain.
  • Paulina Otero Sequeiros
    Paulina Otero Sequeiros (Undergraduate Student):
    Paulina grew up in Mexico City, Mexico and is completing her undergraduate degree of Neurosciences with a double major in Biochemistry. She is currently working with graduate students delivering curcumin using dendrimer nanomolecules as a therapy for Glioblastoma multiforme. She is also involved in the research investigating the migration and bio-distribution of dendrimers in the healthy brain.
  • Sydney Alexus
    Sydney Alexus Climie (Undergraduate Student):
    Sydney grew up in Westland, Michigan and is in her fourth year at Central Michigan University pursuing a double major in Neuroscience and Psychology. She is currently involved with research focused on finding treatments for Stroke and Glioblastoma using dendrimer nanomolecules.
  • Grant Matthew Raymor
    Grant Matthew Raymor (Undergraduate Student):
    Grant grew up in Lake Orion, Michigan and is working on his undergraduate degree in Neuroscience with a double major in Biomedical Sciences at Central Michigan University. Over the summer he works as a Certified Nursing Assistant at Beacon Square Orion. For research he is specializing in dendrimer nanomolecule administration to the stroked rats.
  • Bethany MacDonald
    Bethany MacDonald (Graduate Student):
    Bethany grew up in Gladstone, Michigan. She is an undergraduate perusing Neuroscience with a minor in Psychology. Bethany along with graduate students is working on delivering curcumin as a treatment for Glioblastoma. She is also working on processing the stroked brain tissue following dendrimer nanomolecule therapy.
  • Clayton Malkowski
    Clayton Malkowski (Lab Technician):
    Clayton grew up in Free Soil, Michigan. He is a pre-med student currently in his senior year at Central Michigan University, double majoring in Neuroscience and Biomedical sciences. His current research is focused on the dendrimer nanomolecule based delivery f genes as a treatment for stroke.

Past and present volunteers from the College of Medicine

  • Firas Shalabi
  • Maria Florendo
  • Alex Figacz
  • John Sturgis
  • Anthony Dils
  • Thomas Fagan
  • Joseph Zhou
  • Rachel Kim
  • ​Michael Fana

Recent Publications (since 2014):

  • Dunbar, G. L., Koneru, S., Kolli, N., Sandstrom, M., Maiti, P., & Rossignol, J. (2019). Silencing of the Mutant Huntingtin Gene through CRISPR-Cas9 Improves the Mitochondrial Biomarkers in an In Vitro Model of Huntington’s Disease. Cell Transplantation, 28(4), 460–463. PMID: 30947515
  • Maiti P., Peruzzaro S., Kolli N., Andrews M., Al-Gharaibeh. A., Rossignol J., Dunbar GL (2019) Transplantation of mesenchymal stem cells overexpressing interleukin‐10 induces autophagy response and promotes neuroprotection in a rat model of TBI. Journal of Cellular and Molecular Medicine, 23(8), 5211-5224 PMID: 31162801 3
  • Srinageshwar B, Dils A, Sturgis J, Wedster A, Kathirvelu B, Baiyasi S, Swanson D, Sharma A, Dunbar GL, and Rossignol J. ACS Chemical Neuroscience PMID: 31390175
  • Munro NM†, Srinageshwar B†, Shalabi FL†, Florendo MN, Otero P*, Thompson CE*, Kippe J, Malkowski C*, Climie S*, Stewart AN, Kim RA, Xhou JY, Swanson D, Dunbar GL, Sharma A, Rossignol J. (2019). A Novel Approach to Label Bone Marrow-Derived Mesenchymal Stem Cells with Mixed-Surface PAMAM Dendrimer. Stem Cell Research &Therapy 10(1):71 PubMed PMID: 30819246
  • Florendo M, Figacz A, Srinageshwar B, Sharma A, Swanson D, Dunbar GL, Rossignol J. (2018). Use of Polyamidoamine Dendrimers in Brain Diseases. Molecules. 23(9). PubMed PMID: 30177605
  • Andrews MMM, Peruzzaro S, Raupp S*, Wilks J*, Rossignol J, Dunbar GL. (2018). Using the behavioral flexibility operant task to detect long-term deficits in rats following middle cerebral artery occlusion. Behav Brain Res. S0166-4328(18)30720-4. PubMed PMID: 30107224
  • Story D, Chan E, Munro N, Rossignol J, Dunbar GL. (2018). Latency to startle is reduced in the 5xFAD mouse model of Alzheimer's disease. Behav Brain Res. PubMed PMID: 30055208.
  • Bhupal PK, Anderson KA, Shall GP, Lynn JD*, Hoolsema KS*, Rossignol J, Dunbar GL, Sandstrom MI. (2018). Behavioral and neurochemical responses derived from dopaminergic intrastriatal grafts in hemiparkinsonian rats engaged in a novel motor task. J Neurosci Methods. 18;307:149-163.] PubMed PMID: 29924980.
  • Stewart AN, Kendziorski G*, Deak ZM*, Bartosek NC*, Rezmer BE*, Jenrow K, Rossignol J, Dunbar GL. (2018). Transplantation of Mesenchymal Stem Cells that Overexpress NT-3 Produce Motor Improvements without Axonal Regeneration following Complete Spinal Cord Transections in Rats. Brain Res. PubMed PMID: 29883625.
  • Welchko RM, Hulse TD, Dieffenbach SS*, Shall GP, Huo W*, Siegal LR*, Watters JR*, Leveque XT, Sandstrom MI, Rossignol J, Lu M, and Dunbar GL. Trans-Differentiation of Rat Mesenchymal Stem Cells into Dopaminergic Neurons for Cell Transplantation.  J Stem Cell Res Ther 8:4
  • Shall G, Menosky M*, Decker S*, Nethala P, Welchko R, Leveque X, Lu M, Sandstrom M, Hochgeschwender U, Dunbar G, Rossignol J. (2018) Effects of Passage Number and Differentiation Protocol on the Generation of Dopaminergic Neurons from Rat Bone Marrow-Derived Mesenchymal Stem Cells. Int J Mol Sci. 19(3). PMID:29498713
  • Al-Gharaibeh A, Culver R, Stewart A, Srinageshwar B, Spelde K*,  Frollo L*, Kolli N, Story D, Paladugu L, Anwar S*, Crane A, Wyse R, Maiti P, Dunbar GL,  Rossignol J. (2017) Mouse Induced Neural Stem Cell Transplants Decreased Behavioral Deficits and Attenuated Neuropathological Changes in the YAC128 Mouse Model of Huntington’s Disease. Frontiers in Neuroscience 11:628. PubMed P MID: 29209158
  • Lossia, OV, Conway, MJ, Tree, MO, Williams. RJ, Srinageshwar, B, Dunbar, GL,  Rossignol J. (2018). Zika virus induces astrocyte differentiation in neural stem cells.  J. Neurovirology 24(1):52-61. PubMed P MID: 29063515
  • Kolli, N, Lu, M, Maiti, P, Rossignol, J. and Dunbar, G.L. (2017)  Application of the gene editing tool, CRISPR-Cas9, for treating neurodegenerative diseases. Neurochemistry International S0197-0186(17)30127-4 PubMed PMID:28732771
  • Stewart, A, Kendziorski, G, Deak, Z, Brown, D, Fini, M, Copely, K, Rossignol, J., Dunbar, G, (2017)  SDF-1 and co-transplantation of mesenchymal stem cells and neural stem cells for treating spinal cord injury: a cautionary note. Brain research 1672:91-105 PubMed PMID:28734802
  • Srinageshwar B., Maiti P., Dunbar GL., Rossignol J.  (2017)  Epigenetics, Stem Cells, Cellular Differentiation And Associated Hereditary Neurological Disorders. Handbook of Epigenetics, Second Edition. Chapter 21: Epigenetics, stem cells and cellular differentiation.
  • Stewart, A.N, Matyas, J.J., Welchko, R.M., Goldsmith, A.D., Zeiler, S.E., Hochgeschwender, U., Lu, M., Nan Z., Rossignol, J., Dunbar, G.L. (2017) SDF-1 Overexpression by Mesenchymal Stem Cells Enhances GAP-43-Positive Axonal Growth Following Spinal Cord Injury. Restor Neurol Neurosci 35(4):395-411 PubMed PMID:28598857
  • Matyas, J.J., Stewart, A.N., Goldsmith, A.*, Nan, Z., Skeel, R., Rossignol, J., & Dunbar, G.L. (2017) Effects of bone marrow-derived MSC transplantation on functional recovery in a rat model of spinal cord injury: comparisons of transplant locations and cell concentrations. Cell Transplantation 26 (8):1472-1482. Pubmed PMID: 28901182
  • Kolli N, Lu M, Maiti P, Rossignol J. and Dunbar GL. (2017) CRISPR-Cas9 mediated gene-silencing of the mutant huntingtin gene in in-vitro model of Huntington’s disease. Int. J. Mol. Sci. 18(4), 754, PubMed PMID: 28368337
  • Srinageshwar B, Peruzzaro S, Andrews M, Johnson K, Hietpas A, Clark B, McGuire C, Petersen E, Kippe J, Stewart A, Lossia O, Al-Gharaibeh A, Antcliff A, Culver R, Swanson D, Dunbar G, Sharma A, Rossignol J. (2017) PAMAM dendrimers cross the blood-brain barrier when administered through the carotid artery in C57BL/6J mice. Int. J. Mol. Sci. 18(3), 628, PubMed PMID: 28335421
  • Maiti P, Rossignol J. and Dunbar DL. (2017) Curcumin modulates molecular chaperones and autophagy-lysosomal pathways in vitro after exposure to Aβ42. Journal of Alzheimer's disease and Parkinsonism. 7:299
  • Anderson JD, Pham MT, Contreras Z, Hoon M, Fink KD, Johansson HJ, Rossignol J., Dunbar GL, Showalter M, Fiehn O, Bramlett CS, Bardini RL, Bauer G, Fury B, Hendrix KJ, Chedin F, EL-Andaloussi S, Hwang B, Mulligan MS, Lehtiö, Nolta LA (2016), Mesenchymal stem cell-based therapy for ischemic stroke, Chinese Neurosurgical Journal, 2:36
  • Maiti P, Hall TC, Paladugu L, Kolli N, Learman C, Rossignol J, Dunbar GL (2016). A comparative study of dietary curcumin, nanocurcumin and other classical amyloid binding dyes for labeling and imaging of amyloid plaques in brain tissues of mice from 5x-familial Alzheimer’s disease. Histochemistry and Cell Biology 146(5):609-625, PubMed PMID: 27406082
  • Srinageshwar B, Maiti P, Dunbar GL, Rossignol J. (2016) Role of Epigenetics in Stem Cell Proliferation and Differentiation: Implications for Treating Neurodegenerative Diseases. Int J Mol Sci. 17(2) PubMed PMID: 26848657.
  • Matchynski-Franks JJ, Pappas C, Rossignol J, Reinke T, Fink K, Crane A, Twite A, Lowrance SA, Song C, Dunbar GL. (2016) Mesenchymal stem cells as treatment for behavioral deficits and neuropathology in the 5xFAD mouse model of Alzheimer's disease. Cell Transplant. Epub, PubMed PMID: 26850119.
  • Maiti P, Manna J, Ilavazhagan G, Rossignol J, Dunbar GL. (2015) Molecular regulation of dendritic spine dynamics and their potential impact on synaptic plasticity and neurological diseases. Neurosci Biobehav Rev. 59:208-37. PubMed PMID: 26562682.
  • Rossignol J, Fink KD, Crane AT, Davis KK, Bombard MA, Clerc S, Bavar AM, Lowrance SA, Song C, Witte S, Lescaudron L, Dunbar GL. (2015) Reductions in Behavioral Deficits and Neuropathology in the R6/2 Mouse Model of Huntington’s disease following Transplantation of Bone-Marrow-Derived Mesenchymal Stem Cells is Dependent on Passage Number. Stem Cell Research & Therapy 19; 6(1):9. PubMed Central PMCID: PMC4429666.
  • Lowrance SA, Fink KD, Crane A, Matyas J, Dey ND, Matchynski JJ, Thibo T, Reinke T, Kippe J, Hoffman C, Sandstrom M, Rossignol J, and Dunbar GL (2015) Bone Marrow Derived Mesenchymal Stem Cells Attenuate Cognitive Deficits in an Endothelin-1 Rat Model of Stroke. Restor Neurol Neurosci; 33(4):579-88. PubMed PMID: 23902985.
  • Dunkerson J, Moritz KE, Young J, Pionk T, Fink K, Rossignol J, Dunbar G, Smith JS. (2014) Combining enriched environment and induced pluripotent stem cell therapy results in improved cognitive and motor function following traumatic brain injury. Restor Neurol Neurosci. 32(5):675-87. PubMed PMID: 25079980.
  • Rossignol J, Crane AT, Fink KD, Dunbar GL (2014) Will Undifferentiated Induced Pluripotent Stem Cells Ever have Clinical Utility? J Stem Cell Res Ther 4: 189
  • Fink KD, Crane TA, Rossignol J, Lévêque X, Dues DJ, Huffman LD, Moore AC, Story DT, Dejonge RE, Antcliff A, Hulse TD, Lu M, Lescaudron L, Dunbar GL. (2014) Intrastriatal transplantation of adenovirus-generated induced pluripotent stem cells for treating neuropathological and functional deficits in a rodent model of Huntington’s disease. Stem Cells Translational Medicine, 3(5):620-31. PubMed Central PMCID: PMC4006485.
  • Fink KD, Rossignol J, Lu M, Lévêque X, Hulse TD, Crane AT, Nerriere-Daguin V, Wyse RD, Starski PA, Schloop MT,  Dues DJ,  Witte SJ,  Song C,  Vallier L, Nguyen TH,  Naveilhan P, Anegon I, Lescaudron L, Dunbar GL. (2014) Survival and Differentiation of Adenovirus-Generated Induced Pluripotent Stem Cells Transplanted into the Rat Striatum. Cell Transplantation 23(11):1407-23 PubMed PMID: 23879897.
  • Crane AT, Rossignol J, Dunbar GL, (2014) Use of genetically altered stem cells for the treatment of Huntington's disease. Brain Sci., 4, 202-219 PubMed Central PMCID: PMC4066244.
  • Wyse RD, Dunbar GL, Rossignol J., (2014) Use of Genetically Modified Mesenchymal Stem Cells to Treat Neurodegenerative Diseases. Int. J. Mol. Sci., 15(2), 1719-1745 PubMed Central PMCID: PMC3958818.
  • Fink KD, Rossignol J, Crane TA, Davis KK, Bombard MA, Bavar AM, Clerc S, Lowrance SA, Song C, Lescaudron L, Dunbar GL. (2014) Transplantation of Umbilical-Cord-Blood-derived Mesenchymal Stem Cells into the Striata of R6/2 Mice: Behavioral and Neuropathological Analysis. Stem Cell Research &Therapy, 4:130 PubMed Central PMCID: PMC3854759.
  • Rossignol J, Fink KD, Davis KK, Clerc S, Crane AT, Matchynski JJ, Lowrance SA, Bombard MA, DeKorver N, Lescaudron L, Dunbar GL. (2014) Transplants of adult mesenchymal and neural stem cells provide neuroprotection and behavioral sparing in a transgenic rat model of Huntington's disease. Stem Cells 32(2):500-9. PubMed PMID: 23939879.